Clinical Trials on Lobular Breast Carcinoma In Situ

Total 30850 results

Istituto Oncologico Veneto IRCCS

Recruiting

Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management

Pleomorphic Lobular Breast Carcinoma in Situ | Breast Florid Lobular Carcinoma in Situ

Italy
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer

Estrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma

United States
Auxilio Mutuo Cancer Center

Unknown

"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" (NACprotocol)

Infiltrating Duct and Lobular Carcinoma In Situ | Invasive Lobular Breast Carcinoma | Inflammatory Breast Carcinoma

Puerto Rico
National Cancer Institute (NCI)

Not yet recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

Atypical Hyperplasia of the Breast | Lobular Breast Carcinoma In Situ | Pleomorphic Lobular Breast Carcinoma In Situ

United States, Guam
Ohio State University Comprehensive Cancer Center
Embr Labs, Inc.

Active, not recruiting

EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer

Hot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ

United States
Amy C. Degnim
National Cancer Institute (NCI)

Recruiting

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ

Breast Atypical Lobular Hyperplasia | Breast Atypical Hyperplasia | Breast Lobular Carcinoma in Situ

United States
National Cancer Institute (NCI)

Completed

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

Healthy, no Evidence of Disease | Lobular Breast Carcinoma in Situ

United States
National Cancer Institute (NCI)

Not yet recruiting

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Breast Atypical Hyperplasia

United States
National Cancer Institute (NCI)

Completed

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

Breast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Invasive Breast Carcinoma

United States
Virginia Commonwealth University

Active, not recruiting

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

Breast Cancer | Invasive Breast Carcinoma | Lobular Breast Carcinoma In Situ | Breast Adenocarcinoma | Node-positive Breast Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy (CAREFOR)

Stage IA Breast Cancer | Stage IB Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Lobular Breast Carcinoma | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast Carcinoma

United States
Mayo Clinic

Recruiting

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

Breast Carcinoma | Breast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Lobular Carcinoma In Situ

United States
Institut Bergonié

Completed

Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast (CINNAMOME)

Intraductal Carcinoma and Lobular Carcinoma in Situ

France
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Oxybutynin Chloride in Managing Hot Flashes

Hot Flashes | Breast Carcinoma | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | No Evidence of Disease

United States
Oslo University Hospital
The Research Council of Norway; St. Olavs Hospital

Active, not recruiting

Energy Balance and Breast Cancer Aspects-II (EBBA-II)

Stage I Breast Cancer | Stage II Breast Cancer | DCIS Grade 3 | LCIS, Lobular Carcinoma in Situ

Norway
National Cancer Research Network

Unknown

Genetics of Women With Lobular Carcinoma in Situ of the Breast

Breast Cancer

United Kingdom
National Cancer Institute (NCI)

Not yet recruiting

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Breast Atypical Hyperplasia

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
University of Washington
National Cancer Institute (NCI); National Institute of Nursing Research (NINR)

Completed

Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer (DEEM)

Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ | Atypical Lobular Breast Hyperplasia

United States
National Cancer Institute (NCI)

Completed

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer

Breast Cancer | Ductal Breast Carcinoma in Situ | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Cianna Medical, Inc.

Terminated

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Ductal Breast Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma and other conditions

United States
Ohio State University Comprehensive Cancer Center

Not yet recruiting

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

Breast Carcinoma | Breast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Lobular Carcinoma In Situ | Breast Sclerosing Adenosis

United States
NYU Langone Health
United States Department of Defense

Completed

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

Atypical Ductal Breast Hyperplasia | Lobular Carcinoma in Situ (LCIS) | Atypical Lobular Hyperplasia (ALH) of Breast

United States
Memorial Sloan Kettering Cancer Center

Completed

Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ

Breast Cancer | Invasive Breast Cancer | Lobular Carcinoma

United States
University of Southern California
National Cancer Institute (NCI); California Breast Cancer Research Program

Completed

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Lobular Breast Carcinoma in Situ

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Stage 0 Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ

United States, Canada
Ohio State University Comprehensive Cancer Center

Completed

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Ductal Breast Carcinoma in Situ | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Broccoli Sprout Extract in Treating Patients With Breast Cancer

Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | Lobular Breast Carcinoma | Postmenopausal | Ductal Breast Carcinoma | Ductal Breast Carcinoma In Situ

United States
Ohio State University Comprehensive Cancer Center

Withdrawn

Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer

Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ
Julie Nangia
Incyte Corporation; Translational Breast Cancer Research Consortium

Recruiting

Ruxolitinib for Premalignant Breast Disease (TBCRC042)

Ductal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In Situ

United States
Methodist Health System

Recruiting

Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System

Ductal Carcinoma in Situ | Invasive Lobular Breast Carcinoma

United States
Mayo Clinic
Susan G. Komen Breast Cancer Foundation

Completed

Molecular Breast Imaging in Women With Atypia and LCIS

Lobular Carcinoma in Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia

United States
University of Chicago

Active, not recruiting

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

Lung Metastases | Liver Metastases | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | Invasive Lobular Breast Carcinoma | Central Nervous System Metastases | Tumors Metastatic to Brain | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients

Depression | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Anxiety Disorder | Psychosocial Effects of Cancer and Its Treatment | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Terminated

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Ductal Carcinoma in Situ | Invasive Breast Cancer (Stage I-III) | Lobular Carcinoma in Situ | Lobular Carcinoma | Fatigue Related to Cancer Treatment

United States
St. Joseph Hospital of Orange

Completed

Single Fraction Intraoperative Radiotherapy

Stage 0 Breast Carcinoma | Stage I Breast Carcinoma | Stage II Breast Carcinoma | Invasive Ductal and Invasive Lobular Breast Carcinoma

United States
University of Texas at Austin
Washington University School of Medicine; Ohio State University

Completed

Living Well After Breast Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Ductal Carcinoma in Situ | Lobular Breast Carcinoma | Stage III Breast Cancer | Ductal Breast Carcinoma

United States
Case Comprehensive Cancer Center

Withdrawn

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

Stage I Breast Cancer | HER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast... and other conditions

United States
National Cancer Institute (NCI)

Completed

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | Paget Disease of the Breast | Benign Breast Neoplasm

United States
Northwestern University
National Cancer Institute (NCI); Pfizer; University of California, San Francisco and other collaborators

Recruiting

The PROMISE Study: Duavee in Women With DCIS

Postmenopausal | Ductal Breast Carcinoma In Situ

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Active, not recruiting

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

Ductal Breast Carcinoma In Situ

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast

Cancer Survivor | Invasive Breast Carcinoma | Ductal Breast Carcinoma In Situ

United States
European Institute of Oncology
Istituto Oncologico Veneto IRCCS; Ente Ospedaliero Ospedali Galliera; Istituto...

Not yet recruiting

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion (TOLERANT)

Ductal Carcinoma in Situ | RAD51C Gene Mutation | RAD51D Gene Mutation | PALB2 Gene Mutation | Lobular Carcinoma in Situ | ATM Gene Mutation | CDH1 Gene Mutation | CHEK2 Gene Mutation | BRCA Mutation

Italy
Stanford University

Recruiting

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (NORDIS)

Ductal Breast Carcinoma in Situ

United States
Northwestern University
National Cancer Institute (NCI)

Completed

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

Estrogen Receptor-positive Breast Cancer | Ductal Breast Carcinoma in Situ

United States
Northwestern University
National Cancer Institute (NCI); BHR Pharma, LLC

Recruiting

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Estrogen Receptor Positive | Ductal Breast Carcinoma In Situ

United States
National Cancer Institute (NCI)

Completed

Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ

HER2/Neu Positive | Ductal Breast Carcinoma In Situ

United States

Clinical Trials on Lobular Breast Carcinoma In Situ

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations